Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease

Steven MacLennan, Alberto Briganti, Jeremy M Grimshaw, James N'Dow

Research output: Contribution to journalComment/debate

1 Citation (Scopus)
5 Downloads (Pure)

Abstract

The authors address the thorny issue of the lack of adherence to Clinical Practice Guidelines highlighting high-quality evidence based nonmuscle-invasive bladder cancer (NMIBC) guideline recommendations from the American Urological Association/Society of Urologic Oncology, and the European Association of Urology as exemplars [1]. In particular, they emphasise three strong practice recommendations underpinned by high-quality evidence: immediate intravesical installation of chemotherapy in patients with presumed low-risk or intermediate-risk NMIBC, the performance of a second transurethral resection for high-risk NMIBC, and the administration of adjuvant intravesical Bacillus Calmette–Guérin immunotherapy in high-risk NMIBC. Data from North America, Europe, and Australia are cited illustrating variability and general lack of adherence (ranging from 0.5% to 65%) to these recommendations.
Original languageEnglish
Pages (from-to)689
Number of pages1
JournalEuropean Urology
Volume71
Issue number4
Early online date28 Dec 2016
DOIs
Publication statusPublished - 1 Apr 2017

Fingerprint

Guideline Adherence
Urinary Bladder Neoplasms
Intravesical Administration
North America
Practice Guidelines
Immunotherapy
Bacillus
Guidelines
Drug Therapy

Cite this

Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease. / MacLennan, Steven; Briganti, Alberto; Grimshaw, Jeremy M; N'Dow, James.

In: European Urology, Vol. 71, No. 4, 01.04.2017, p. 689.

Research output: Contribution to journalComment/debate

MacLennan, Steven ; Briganti, Alberto ; Grimshaw, Jeremy M ; N'Dow, James. / Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease. In: European Urology. 2017 ; Vol. 71, No. 4. pp. 689.
@article{8a065415cc9d4bcbb43eea7a02a849a2,
title = "Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease",
abstract = "The authors address the thorny issue of the lack of adherence to Clinical Practice Guidelines highlighting high-quality evidence based nonmuscle-invasive bladder cancer (NMIBC) guideline recommendations from the American Urological Association/Society of Urologic Oncology, and the European Association of Urology as exemplars [1]. In particular, they emphasise three strong practice recommendations underpinned by high-quality evidence: immediate intravesical installation of chemotherapy in patients with presumed low-risk or intermediate-risk NMIBC, the performance of a second transurethral resection for high-risk NMIBC, and the administration of adjuvant intravesical Bacillus Calmette–Gu{\'e}rin immunotherapy in high-risk NMIBC. Data from North America, Europe, and Australia are cited illustrating variability and general lack of adherence (ranging from 0.5{\%} to 65{\%}) to these recommendations.",
author = "Steven MacLennan and Alberto Briganti and Grimshaw, {Jeremy M} and James N'Dow",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.eururo.2016.12.019",
language = "English",
volume = "71",
pages = "689",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease

AU - MacLennan, Steven

AU - Briganti, Alberto

AU - Grimshaw, Jeremy M

AU - N'Dow, James

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The authors address the thorny issue of the lack of adherence to Clinical Practice Guidelines highlighting high-quality evidence based nonmuscle-invasive bladder cancer (NMIBC) guideline recommendations from the American Urological Association/Society of Urologic Oncology, and the European Association of Urology as exemplars [1]. In particular, they emphasise three strong practice recommendations underpinned by high-quality evidence: immediate intravesical installation of chemotherapy in patients with presumed low-risk or intermediate-risk NMIBC, the performance of a second transurethral resection for high-risk NMIBC, and the administration of adjuvant intravesical Bacillus Calmette–Guérin immunotherapy in high-risk NMIBC. Data from North America, Europe, and Australia are cited illustrating variability and general lack of adherence (ranging from 0.5% to 65%) to these recommendations.

AB - The authors address the thorny issue of the lack of adherence to Clinical Practice Guidelines highlighting high-quality evidence based nonmuscle-invasive bladder cancer (NMIBC) guideline recommendations from the American Urological Association/Society of Urologic Oncology, and the European Association of Urology as exemplars [1]. In particular, they emphasise three strong practice recommendations underpinned by high-quality evidence: immediate intravesical installation of chemotherapy in patients with presumed low-risk or intermediate-risk NMIBC, the performance of a second transurethral resection for high-risk NMIBC, and the administration of adjuvant intravesical Bacillus Calmette–Guérin immunotherapy in high-risk NMIBC. Data from North America, Europe, and Australia are cited illustrating variability and general lack of adherence (ranging from 0.5% to 65%) to these recommendations.

U2 - 10.1016/j.eururo.2016.12.019

DO - 10.1016/j.eururo.2016.12.019

M3 - Comment/debate

VL - 71

SP - 689

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 4

ER -